BTCC / BTCC Square / Global Cryptocurrency /
Tempus AI Stock Rises on FDA Clearance for RNA-Based Diagnostic Tool

Tempus AI Stock Rises on FDA Clearance for RNA-Based Diagnostic Tool

Global Cryptocurrency
Release Time:
2025-09-23 12:16:03
0
BTCCSquare news:

Tempus AI shares gained in premarket trading following FDA clearance for its Tempus xR IVD device, a breakthrough in tumor analysis. The RNA-sequencing tool identifies molecular pathways in cancer progression, enabling targeted patient selection for clinical trials.

Monday's trading saw TEM hit an all-time high of $97.39 before closing down 2.7%. The premarket rebound suggests sustained investor confidence in the company's data-driven oncology solutions. Tempus' technology positions it as a key partner for biopharma firms seeking efficient trial methodologies.

Articles on this site are sourced from public networks or curated by AI for informational purposes only and do not represent BTCC’s views. Original rights belong to the respective authors. For copyright concerns, please contact [email protected]. BTCC assumes no liability for the accuracy, timeliness, or completeness of this information, and disclaims all liability arising from reliance on such content. This content is for reference only and should not be taken as investment, legal, or commercial advice.

|Square

Get the BTCC app to start your crypto journey

Get started today Scan to join our 100M+ users